Glentek 50 mg compresse rivestite con film ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)1

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000282-37-IT
(EUCTR)
26/02/202017/06/2021Riluzole in spinocerebellar ataxia type 7Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase - RISCA7 Spinocerebellar ataxia type 7 (SCA7)
MedDRA version: 20.0;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Glentek 50 mg film-coated tablets
Product Name: Glentek 50 mg compresse rivestite con film
Product Code: [Glentek 50 mg compresse rivestite con film]
INN or Proposed INN: Riluzolo
DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
34Phase 2United States;Italy